- Home
- EVAX vs PPBT Comparison
EVAX vs PPBT Comparison
Compare EVAX & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- PPBT
- Stock Information
- Founded
- EVAX 2008
- PPBT 2010
- Country
- EVAX Denmark
- PPBT Israel
- Employees
- EVAX N/A
- PPBT N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- PPBT Health Care
- Exchange
- EVAX Nasdaq
- PPBT Nasdaq
- Market Cap
- EVAX 17.8M
- PPBT 2.1M
- IPO Year
- EVAX 2021
- PPBT N/A
- Fundamental
- Price
- EVAX $2.94
- PPBT $0.60
- Analyst Decision
- EVAX Strong Buy
- PPBT Strong Buy
- Analyst Count
- EVAX 2
- PPBT 1
- Target Price
- EVAX $10.00
- PPBT $33.00
- AVG Volume (30 Days)
- EVAX 71.6K
- PPBT 2.9M
- Earning Date
- EVAX 10-30-2025
- PPBT 11-14-2025
- Dividend Yield
- EVAX N/A
- PPBT N/A
- EPS Growth
- EVAX N/A
- PPBT N/A
- EPS
- EVAX N/A
- PPBT N/A
- Revenue
- EVAX $3,176,000.00
- PPBT N/A
- Revenue This Year
- EVAX N/A
- PPBT N/A
- Revenue Next Year
- EVAX $425.50
- PPBT N/A
- P/E Ratio
- EVAX N/A
- PPBT N/A
- Revenue Growth
- EVAX 1042.45
- PPBT N/A
- 52 Week Low
- EVAX $1.20
- PPBT $0.53
- 52 Week High
- EVAX $17.20
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- EVAX 52.53
- PPBT 32.32
- Support Level
- EVAX $2.81
- PPBT N/A
- Resistance Level
- EVAX $3.04
- PPBT $2.36
- Average True Range (ATR)
- EVAX 0.20
- PPBT 0.14
- MACD
- EVAX -0.01
- PPBT -0.10
- Stochastic Oscillator
- EVAX 71.19
- PPBT 25.54
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.